Neovacs S.A. risk profile
56 Elevated one input has moved against it
Measured 1 September 2026 from 0LW0's filed statements. Recomputed nightly.
56 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 91 | Acute | Stable | Drawdown from the 52-week high — 90.8% |
| Operating pressure | 44 | Elevated | Worsening | Costs outgrowing revenue — +40.7 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 19 | Contained | Worsening | Current ratio — 0.63x |
| Competitive position | 56 | Elevated | Stable | Operating-margin gap against peers — -3,499.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.